Trial Profile
Phase II Trial of Ixabepilone and Carboplatin With or Without Bevacizumab in Patients With Previously Untreated Advanced Non-Small-Cell Lung Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Dec 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Carboplatin (Primary) ; Ixabepilone (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors SCRI Development Innovations
- 01 Sep 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 12 Jun 2012 Planned End Date changed from 1 Sep 2012 to 1 Sep 2013 as reported by ClinicalTrials.gov record.
- 04 Jan 2012 Planned end date changed from 1 Sep 2011 to 1 Sep 2012 as reported by ClinicalTrials.gov.